Cytosorbents (CTSO) Revenue (2011 - 2026)

Cytosorbents' Revenue history runs 16 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• Quarterly Revenue rose 1.57% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.2 million (up 5.28% YoY) and the FY2025 annual result came in at $37.1 million, up 4.12% from the prior year.
• Revenue was $8.9 million for Q1 2026 at Cytosorbents, down from $9.2 million in the prior quarter.
• Across five years, Revenue topped out at $9.6 million in Q2 2025 and bottomed at $8.1 million in Q3 2022.
• A 5-year average of $9.0 million and a median of $8.9 million in 2026 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue slipped 29.35% — and 2023, when it advanced 10.89%.
• Cytosorbents' Revenue stood at $9.4 million in 2022, then retreated by 7.69% to $8.7 million in 2023, then gained by 5.57% to $9.2 million in 2024, then increased by 0.91% to $9.2 million in 2025, then slipped by 4.01% to $8.9 million in 2026.
• Business Quant data shows CTSO's Revenue at $8.9 million in Q1 2026, $9.2 million in Q4 2025, and $9.5 million in Q3 2025.